Unknown

Dataset Information

0

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.


ABSTRACT:

Objectives

This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma.

Materials and methods

Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study.

Results

Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response.

Conclusion

SC-002 treatment was associated with systemic toxicity and limited efficacy.

SUBMITTER: Morgensztern D 

PROVIDER: S-EPMC8173700 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6449265 | biostudies-literature
| S-EPMC6825905 | biostudies-other
| S-EPMC5061374 | biostudies-literature
| S-EPMC9552065 | biostudies-literature
| S-EPMC7802130 | biostudies-literature
| S-EPMC8832809 | biostudies-literature
| S-EPMC4995776 | biostudies-literature
| S-EPMC6691699 | biostudies-literature
| S-EPMC7653155 | biostudies-literature
| S-EPMC10607103 | biostudies-literature